Author: admin

Vascular Malformations Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Vascular Malformations Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Vascular Malformations pipeline landscape. It covers the Vascular Malformations pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vascular Malformations pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Vascular Malformations Pipeline. Dive into DelveInsight’s comprehensive report today! @ Vascular Malformations Pipeline Outlook

Key Takeaways from the Vascular Malformations Pipeline Report

  • In June 2025, Xuanwu Hospital, Beijing announced a study is a single-arm exploratory trial conducted by Xuanwu Hospital, Capital Medical University, aiming to evaluate the efficacy and safety of everolimus monotherapy in adult patients with vascular malformations.
  • In June 2025, University of Arkansas announced study and potential risks, all patients giving informed consent will go undergo a screening period to determine eligibility for study entry. Patients who meet the eligibility requirements will be given cobimetinib to take by mouth once daily at the same time each day for 21 days and then have 7 days with no treatment. Patients will receive cobimetinib as a tablet (adult) or as a liquid (child).
  • In June 2025, Relay Therapeutics Inc. organized a Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.
  • DelveInsight’s Vascular Malformations Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Vascular Malformations treatment.
  • The leading Vascular Malformations Companies such as Nobelpharma, Venthera, ONY Biotech, Vaderis Therapeutics, BridgeBio Pharma, Genentech Inc. and others.
  • Promising Vascular Malformations Pipeline Therapies such as Everolimus, Alpelisib, Cobimetinib, CYH33, RLY-2608, PTX-022, TARA-002, Ticagrelor, Alpelisib (BYL719), SRM003, and others.

Stay ahead with the most recent pipeline outlook for Vascular Malformations. Get insights into clinical trials, emerging therapies, and leading companies with Vascular Malformations @ Vascular Malformations Treatment Drugs

Vascular Malformations Emerging Drugs Profile

  • VT 30: Venthera

VT 30, is a novel investigational therapy is designed to target the genetic drivers of venous (VM), lymphatic (LM), and venolymphatic malformations (VLM) at their source by delivering a potent PI3Kα inhibitor directly to affected tissue. The majority of these cutaneous vascular malformations are driven by somatic mutations in the PIK3CA and TEK genes. These mutations result in overactivation of the PI3K pathway and have been identified as the root cause of the vast majority of VMs, LMs, and VLMs. Because BBP-681 is applied directly to skin lesions, it may minimize complications seen with systemic treatments.

  • NPC-12: Nobelpharma

NPC-12, is an investigational drug being developed by Nobelpharma.It is acts as a T lymphocyte inhibitor. Currently, the drug is being evaluated at Phase III for the treatment of vascular anomalies.

The Vascular Malformations Pipeline Report Provides Insights into-

  • The report provides detailed insights about companies that are developing therapies for the treatment of Vascular Malformations with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vascular Malformations Treatment.
  • Vascular Malformations Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Vascular Malformations Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vascular Malformations market

Explore groundbreaking therapies and clinical trials in the Vascular Malformations Pipeline. Access DelveInsight’s detailed report now! @ New Vascular Malformations Drugs

Vascular Malformations Companies

Nobelpharma, Venthera, ONY Biotech, Vaderis Therapeutics, BridgeBio Pharma, Genentech Inc. and others.

Vascular Malformations pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Vascular Malformations Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Unveil the future of Vascular Malformations Treatment. Learn about new drugs, Vascular Malformations Pipeline developments, and key companies with DelveInsight’s expert analysis @ Vascular Malformations Market Drivers and Barriers

Scope of the Vascular Malformations Pipeline Report

  • Coverage- Global
  • Vascular Malformations Companies- Nobelpharma, Venthera, ONY Biotech, Vaderis Therapeutics, BridgeBio Pharma, Genentech Inc. and others.
  • Vascular Malformations Pipeline Therapies- Everolimus, Alpelisib, Cobimetinib, CYH33, RLY-2608, PTX-022, TARA-002, Ticagrelor, Alpelisib (BYL719), SRM003, and others.
  • Vascular Malformations Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Vascular Malformations Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Vascular Malformations Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth Pipeline Report today! @ Vascular Malformations Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Vascular Malformations: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Vascular Malformations– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NPC-12: Nobelpharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase I/II)
  11. VT 30: Venthera
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Vascular Malformations Key Companies
  21. Vascular Malformations Key Products
  22. Vascular Malformations- Unmet Needs
  23. Vascular Malformations- Market Drivers and Barriers
  24. Vascular Malformations- Future Perspectives and Conclusion
  25. Vascular Malformations Analyst Views
  26. Vascular Malformations Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vascular-malformations-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vascular Malformations Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Non-Hodgkin Lymphoma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non-Hodgkin Lymphoma Treatment Landscape. Click here to read more @ Non-Hodgkin Lymphoma Pipeline Outlook

Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report

  • In June 2025, AstraZeneca announced a study is designed to evaluate the safety, tolerability, PK, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
  • In June 2025, Genmab conducted a study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed.
  • In June 2025, Artiva Biotherapeutics Inc. organized clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients.
  • DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment.
  • The leading Non-Hodgkin Lymphoma Companies such as Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.
  • Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others.

Discover groundbreaking developments in Non-Hodgkin Lymphoma Therapies! Gain in-depth knowledge of key Non-Hodgkin Lymphoma clinical trials, emerging drugs, and market opportunities @ Non-Hodgkin Lymphoma Clinical Trials Assessment

Non-Hodgkin Lymphoma Emerging Drugs Profile

  • Golcadomide: Bristol Myers Squibb

Golcadomide is a novel cereblon E3 ligase modulator (CELMoD) being investigated for the treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). In combination with R-CHOP chemotherapy, it has shown promising antitumor activity in high-risk DLBCL patients, with a high overall response rate (ORR) and complete metabolic response (CMR). Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-Hodgkin Lymphoma. 

  • MEN 1703: Ryvu Therapeutics

MEN1703 (SEL24) is a clinical-stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. MEN1703 is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address a disease that has progressed following FLT3 inhibition. Preclinical data suggests therapeutic potential in both hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize MEN1703 (SEL24). Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.

  • LP-168: Guangzhou Lupeng Pharmaceutical

LP-168 is a third-generation, orally active, irreversible EGFR tyrosine kinase inhibitor (TKI) developed by Guangzhou Lupeng Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It is designed to target mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. LP-168 has shown promising preclinical activity and is currently in clinical trials. The company is exploring its use in both first-line and resistant EGFR-mutant NSCLC settings. Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.

  • DR-0201: Dren Bio

DR-0201 is an investigational drug developed by D.R. Pharmatech, designed as a novel anti-cancer agent targeting HER2-expressing tumors, particularly in gastric and breast cancers. It is a HER2-targeting antibody-drug conjugate (ADC) that combines a monoclonal antibody with a cytotoxic payload to selectively kill cancer cells while minimizing damage to healthy tissue. DR-0201 aims to overcome resistance seen with existing HER2 therapies. The product is currently undergoing preclinical or early-phase clinical evaluation. Currently the drug is in Phase I stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.

  • ETR-7072: EntreChem

ETR-7072 is an investigational small-molecule drug developed by EntreChem, designed to target cancer by modulating transcriptional programs involved in tumor growth and survival. It is part of EntreChem’s novel class of natural product-inspired compounds with multi-targeted activity, potentially affecting epigenetic regulators and oncogenic pathways. ETR-7072 shows promise in preclinical models for treating aggressive and resistant cancers. The compound is currently in early-stage development, with ongoing studies to assess its safety and efficacy. Currently the drug is in Preclinical stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.

The Non-Hodgkin Lymphoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
  • Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market

Stay informed about the Non-Hodgkin Lymphoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Non-Hodgkin Lymphoma Unmet Needs

Non-Hodgkin Lymphoma Companies

Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.

Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Transform your understanding of the Non-Hodgkin Lymphoma Pipeline! See the latest progress in drug development and clinical research @ Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Non-Hodgkin Lymphoma Pipeline Report

  • Coverage- Global
  • Non-Hodgkin Lymphoma Companies- Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.
  • Non-Hodgkin Lymphoma Pipeline Therapies- Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others.
  • Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Research-Access the Full Non-Hodgkin Lymphoma Pipeline Analysis Today! @ Non-Hodgkin Lymphoma Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Non-Hodgkin Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Hodgkin Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Golcadomide: Bristol Myers Squibb
  9. Mid Stage Products (Phase II)
  10. MEN 1703: Ryvu Therapeutics
  11. Early Stage Products (Phase I)
  12. DR-0201: Dren Bio
  13. Preclinical and Discovery Stage Products
  14. ETR-7072: EntreChem
  15. Inactive Products
  16. Non-Hodgkin Lymphoma Key Companies
  17. Non-Hodgkin Lymphoma Key Products
  18. Non-Hodgkin Lymphoma- Unmet Needs
  19. Non-Hodgkin Lymphoma- Market Drivers and Barriers
  20. Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
  21. Non-Hodgkin Lymphoma Analyst Views
  22. Non-Hodgkin Lymphoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Hodgkin Lymphoma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

NASH Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight’s comprehensive report today! @ NASH Pipeline Outlook

Key Takeaways from the NASH Pipeline Report

  • In June 2025, Akero Therapeutics Inc. announced a study of Phase 2b evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH).
  • In June 2025, NGM Biopharmaceuticals Inc. conducted a study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.
  • In June 2025, Altimmune Inc. organized a phase 2 study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH).
  • In June 2025, Novo Nordisk A/S announced a study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
  • In June 2025, 89bio Inc. conducted a study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
  • DelveInsight’s NASH Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for NASH treatment.
  • The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
  • Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.

Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs

NASH Emerging Drugs Profile

  • Semaglutide: Novo Nordisk A/S

Semaglutide, developed by Novo Nordisk, is a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) being explored for the treatment of liver fibrosis and Non-Alcoholic Fatty Liver Disease (NAFLD). It aims to improve liver histology and promote NAFLD resolution. Semaglutide has demonstrated improvements in lipid profiles, liver steatosis, and fibrosis parameters, as well as reductions in BMI among patients with type 2 diabetes and obesity with NAFLD. Semaglutide exerts beneficial effects on NAFLD through several mechanisms. It enhances incretin function by activating GLP-1 receptors. Beyond weight loss-related benefits, semaglutide has antioxidative effects and reduces mitochondrial damage, which plays a central role in the pathogenesis and progression of NAFLD. Additionally, it has anti-inflammatory effects, inhibiting the upregulation of pro-inflammatory factors and down-regulating the expression of inflammatory factors. Novo Nordisk also announced that the US Food and Drug Administration has accepted the supplemental New Drug Application (sNDA) and granted Priority Review for Wegovy® (semaglutide) injection 2.4 mg to treat noncirrhotic MASH in adults with moderate to advanced liver scarring (fibrosis). Currently, the drug is registered for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • Aramchol: Galmed Pharmaceuticals

Aramchol (Arachidyl Amido Cholanoic Acid) is a first-in-class, novel synthetic small molecule, a conjugate of Cholic Acid and Arachidic Acid, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of NASH (Nonalcoholic Steatohepatitis) and fibrosis. Aramchol’s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation, and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol, by targeting this single receptor, induces a cascade of events that leads to two main changes; in hepatocytes, Aramchol elevates the fatty acids oxidation (or in other words – fat burn) and influences AMPK, which results also in reducing glycemic parameters; and in hepatic stellate cells, Aramchol has been shown to down-regulate the expression and activity of stearoyl-CoA desaturase-1 (SCD-1), resulting in a direct effect on fibrogenesis. Currently, the drug is in Phase III stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • Survodutide: Boehringer Ingelheim

Survodutide is an innovative dual GLP-1/glucagon receptor agonist designed to address metabolic dysfunction and liver disorders. By targeting key metabolic pathways, Survodutide helps regulate glucose metabolism, lipid accumulation, and inflammatory responses, which are critical factors in the progression of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This therapeutic approach aims to reduce liver fat, improve insulin sensitivity, and support liver health, making it a potential treatment option for patients at risk of liver fibrosis and cirrhosis. As part of the evolving landscape of metabolic and liver disease management, Survodutide represents a novel strategy for addressing liver dysfunction while promoting overall metabolic balance. Currently, the drug is in Phase III stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • AZD2693: AstraZeneca

AZD2693 is a liver-targeted antisense oligonucleotide against PNPLA3 mRNA. AZD2693 lowers the mRNA expression of PNPLA3 in patients that are homozygotes for the 148M risk allele thereby reducing an important disease driver for NASH. AZD2693 has been evaluated in 3-month repeat dose subcutaneous toxicity study in preclinical species. Findings were consistent with typical class effects of ASOs, including histiocytic infiltration in multiple tissues and evidence of ASO accumulation in liver and spleen. No effects were attributed to the reduction in PNPLA3. Preclinical safety pharmacology studies have also been conducted with no effects on the respiratory, cardiovascular, and central and peripheral nervous systems. Under preclinical pharmacology, Murine PNPLA3 tool ASO has been shown to reduce liver steatosis, inflammation and fibrosis in homozygous PNPLA3 148M knock-in mice. Currently, the drug is in Phase II stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • ALN-HSD: Regeneron Pharmaceuticals

ALN-HSD is an investigational, subcutaneously administered RNAi therapeutic targeting HSD17B13 for the treatment of NASH. It is being developed by Regeneron in collaboration with Alnylam Pharmaceuticals following the identification of a loss-of-function variant in HSD17B13 that is associated with a reduced risk of chronic liver disease and progression from steatosis to steatohepatitis. Studies have shown that Individuals with two copies of the loss-of-function variant in the HSD17B13 gene, which encodes the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13, had lower risk of alcoholic cirrhosis and nonalcoholic cirrhosis than individuals with two functioning copies of the gene. These individuals also had lower risk of alcoholic liver disease and 30 percent lower risk of nonalcoholic liver disease than people with functioning copies of the gene. The variant is also associated with a reduced risk of NASH, suggesting that loss of HSD17B13 function protects from progression to later, more clinically-impactful stages of liver disease. Currently, the drug is in Phase II stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).

The NASH Pipeline Report Provides Insights into-

  • The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment.
  • NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market

Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight’s detailed report now! @ New NASH Drugs

NASH Companies

Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.

Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

NASH Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight’s expert analysis @ NASH Market Drivers and Barriers

Scope of the NASH Pipeline Report

  • Coverage- Global
  • NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
  • NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.
  • NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Nonalcoholic Steatohepatitis: Overview
  4. NASH Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lanifibranor: Inventiva Pharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. TERN-501: Terns Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. LY3849891: Eli Lilly and Company
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Nonalcoholic Steatohepatitis Key Companies
  21. Nonalcoholic Steatohepatitis Key Products
  22. Nonalcoholic Steatohepatitis- Unmet Needs
  23. Nonalcoholic Steatohepatitis- Market Drivers and Barriers
  24. Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
  25. Nonalcoholic Steatohepatitis Analyst Views
  26. Nonalcoholic Steatohepatitis Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NASH Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Neurofibromatoses Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Neurofibromatoses pipeline landscape. It covers the Neurofibromatoses pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibromatoses pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Neurofibromatoses Treatment Landscape. Click here to read more @ Neurofibromatoses Pipeline Outlook

Key Takeaways from the Neurofibromatoses Pipeline Report

  • In June 2025, Healx Limited announced a phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.
  • In June 2025, Novartis Pharmaceuticals conducted a study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
  • DelveInsight’s Neurofibromatoses pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Neurofibromatoses treatment.
  • The leading Neurofibromatoses Companies such as Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.
  • Promising Neurofibromatoses Pipeline Therapies such as trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others.

Discover groundbreaking developments in Neurofibromatoses Therapies! Gain in-depth knowledge of key Neurofibromatoses emerging drugs, and market opportunities @ Neurofibromatoses Clinical Trials Assessment

Neurofibromatoses Emerging Drugs Profile

  • FCN-159: Shanghai Fosun Pharmaceutical

FCN-159 is a novel, proprietary and highly potent inhibitor of mitogen-activated protein kinase kinase enzymes (MEK). It is being developed by Fochon as a monotherapy and in combination to treat solid tumors. MEK is a key member in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Dysregulation of this pathway frequently occurs in many types of cancer, in particular through mutations in BRAF, KRAS and NRAS. Currently, the drug is in Phase III stage of its development for the treatment of Neurofibromatoses.

  • HLX-1502: Healx Limited

HLX-1502 is an investigational, orally administered small molecule drug developed by Healx for treating Neurofibromatosis Type 1 (NF1), a rare genetic disorder marked by tumor growth along nerves. HLX-1502 was discovered using Healx’s proprietary AI platform, which accelerates the identification of potential drug candidates. The therapy has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, underscoring its potential significance for the NF1 community. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Neurofibromatosis Type 1.

  • PAS-004: Pasithea Therapeutics Corp.

PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK). Currently, the drug is in the Phase I stage of its development for the treatment of Neurofibromatosis Type 1.

The Neurofibromatoses Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatoses with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatoses Treatment.
  • Neurofibromatoses Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Neurofibromatoses Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatoses market

Stay informed about the Neurofibromatoses pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Neurofibromatoses Unmet Needs

Neurofibromatoses Companies

Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.

Neurofibromatoses Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Neurofibromatoses Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Transform your understanding of the Neurofibromatoses Pipeline! See the latest progress in drug development and clinical research @ Neurofibromatoses Market Drivers and Barriers, and Future Perspectives

Scope of the Neurofibromatoses Pipeline Report

  • Coverage- Global
  • Neurofibromatoses Companies- Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.
  • Neurofibromatoses Pipeline Therapies- Trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others.
  • Neurofibromatoses Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Neurofibromatoses Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Research-Access the Full Neurofibromatoses Pipeline Analysis Today! @ Neurofibromatoses Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Neurofibromatoses: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Neurofibromatoses– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. FCN-159: Shanghai Fosun Pharmaceutical
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. HLX-1502: Healx Limited
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PAS-004: Pasithea Therapeutics Corp.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Neurofibromatoses Key Companies
  21. Neurofibromatoses Key Products
  22. Neurofibromatoses- Unmet Needs
  23. Neurofibromatoses- Market Drivers and Barriers
  24. Neurofibromatoses- Future Perspectives and Conclusion
  25. Neurofibromatoses Analyst Views
  26. Neurofibromatoses Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neurofibromatoses-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Digital Education Market Outlook 2030: Growth Strategy, Outlook, Opportunities, Trends, and Top Key Player

“Udemy (US), Coursera (US), LinkedIn Learning (US), Pluralsight (US), edX (US), Udacity (US), Intellipaat (India), Swayam (India), Veranda Learning (India), Alison (Ireland).”
Digital Education Market by Learning Model (Self-paced, Blended, Microlearning, Adaptive, Mobile), Course Type (Academic, Test Preparation, Professional Certification & Skill Development, Vocational Training, Corporate Training) – Global Forecast to 2030.

The digital education market is expected to expand at a compound annual growth rate (CAGR) of 24.2% from USD 32.36 billion in 2025 to USD 95.70 billion by 2030. Digital education platforms are online systems that provide professionals, organizations, and students with flexible and easily available learning resources, experiences, and information. The market for digital education is expanding quickly due to rising demand for remote learning, upskilling, and individualized learning. In contrast to conventional classroom approaches, modern platforms offer sophisticated features like AI-driven content recommendations, adaptive learning paths, interactive assessments, and real-time progress tracking, which improve learner engagement and outcomes. Furthermore, seamless access at any time and from any location is made possible by integrations with mobile apps, virtual laboratories, and collaboration tools, which support a variety of learning methods.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7751828

Based on delivery mode, synchronous learning segment to lead market during forecast period

Synchronous learning has the ability to replicate traditional classroom experiences through real-time interactions. It enables students and faculty to meet in real-time via video conferencing, webinars, and virtual classrooms, promoting prompt feedback, discussions, and collaborative learning. This delivery mode has gained significant traction, particularly in corporate training, college education, and professional development, where interactive sessions enhance knowledge and interest. Its growth is further stimulated by the increased use of advanced communication devices, the ease of internet access, and the ever-growing need for a more personalized and interactive learning process. Moreover, the rising popularity of synchronous platforms among organizations and institutions helps maintain the structure of learning processes while offering flexibility and accessibility to geographically distributed learners, highlighting this segment’s significance in the evolving digital education market.

Based on learning model, blended learning segment to register highest CAGR during forecast period

Blended learning meets the needs of various learning styles. It enhances student engagement by offering the opportunity to study in a flexible environment while combining direct communication with instructors and peers. Educational institutions and organizations rapidly adopt this model to provide personalized learning, improve knowledge retention, and support skill enhancement. Blended learning can be even more effective when incorporating modern technologies like AI, data analytics, and virtual simulations, which offer real-time feedback and dynamic learning paths. Additionally, compared to other models, it optimizes resources, scalability, and cost-effectiveness, making it a practical choice for academic and corporate training settings. These benefits drive the increasing market demand and high adoption of blended learning solutions in the digital education market.

Based on region, Asia Pacific to register highest CAGR during forecast period

Asia Pacific is projected to achieve the highest CAGR in the digital education market throughout the forecast period, driven by strong government policies, high technology penetration, and increasing internet connectivity. Digital infrastructure, including the expansion of broadband internet in countries such as India, China, Indonesia, and Vietnam, is improving access to online education. Initiatives like the National Digital Education Architecture of India and efforts in the ASEAN countries aim to enhance digital literacy and provide equitable education. The growing demand for flexible learning models, particularly hybrid and lifelong learning, is also fueling market growth. The region’s large population of youth, combined with a booming edtech startup scene, creates a strong demand for innovative, localized digital education solutions. Collaborations between international technology corporations and local organizations, such as SkillsBuild by IBM and Acer Education Platforms that utilize artificial intelligence, further facilitate faster adoption among people of varying socio-economic backgrounds.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=7751828

Unique Features in the Digital Education Market

Digital education platforms leverage AI and data analytics to create customized learning experiences tailored to each learner’s pace, preferences, and skill level. This feature enhances engagement and improves learning outcomes by catering to individual strengths and weaknesses.

Gamification elements like badges, leaderboards, and challenges are integrated into digital learning platforms to boost motivation and participation. Interactive multimedia content such as videos, simulations, and quizzes transforms traditional learning into a dynamic, immersive experience.

With the widespread use of smartphones and tablets, many digital education solutions are designed to be mobile-first. This ensures anytime, anywhere access to learning materials, enabling flexibility and convenience, particularly for remote and on-the-go learners.

Advanced analytics tools provide educators and administrators with real-time insights into learner performance, engagement metrics, and progress tracking. This allows for timely interventions and informed decision-making to improve learning strategies.

The use of VR and AR technologies enhances experiential learning by simulating real-world environments. This is especially useful in fields like medical training, engineering, and vocational education, offering learners hands-on experience in a safe, controlled digital setting.

Major Highlights of the Digital Education Market

The digital education market has witnessed exponential growth driven by the global shift towards online and hybrid learning models. Factors such as increasing internet penetration, smartphone adoption, and the rise of remote work and learning have accelerated market expansion.

Governments and educational institutions worldwide are investing heavily in digital education infrastructure. Initiatives like digital literacy programs, national e-learning platforms, and funding for EdTech startups are key drivers of market development.

A significant highlight is the rise of EdTech startups offering innovative solutions ranging from K-12 learning to adult upskilling. These companies are disrupting traditional education models with AI-based tutors, immersive technologies, and subscription-based learning platforms.

The demand for reskilling and upskilling among professionals is fueling growth in online courses, certifications, and corporate training programs. This shift reflects a move from degree-centric education to a skills-first learning economy.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=7751828

Top Companies in the Digital Education Market

Major vendors belong to the North American and Asia Pacific regions, such as Udemy (US), Coursera (US), LinkedIn Learning (US), Pluralsight (US), edX (US), Udacity (US), Intellipaat (India), Swayam (India), Veranda Learning (India), and Alison (Ireland). These players can focus on creating new alliances and relationships. Major firms have used various tactics to increase their market domination, including partnerships, contracts, mergers & acquisitions, and product launches.

Udemy

Udemy is a global online learning platform that offers a wide range of courses designed to upskill individuals, professionals, and organizations. Udemy functions mainly on a marketplace model, which delivers 200,000 courses across various fields, including business and technology, personal development, and creative skills. The platform permits teachers worldwide to develop courses, which they distribute to learners in more than 190 countries. The platform offers self-paced, flexible learning options, including video content, quizzes, and mobile access.

In the digital education market, Udemy is unique with its robust enterprise solution, Udemy Business, which provides hand-curated bundles of courses for business clients wanting to build employee skills and promote continuing learning. The B2B division has seen rapid growth as firms prioritize up-skilling in emerging technologies, leadership, and soft skills. The platform’s personalization based on data, localized content, and global reach places it on an equal footing with academically oriented and enterprise training providers. Additionally, Udemy is investing increasingly in AI-powered functionality to improve outcomes and course recommendations, placing it firmly at the forefront of the evolving digital learning landscape.

Coursera

Coursera is an international online learning platform that provides access to high-quality education by leading universities and industry leaders. Coursera works with over 300 institutions to offer over 6,000 courses, specializations, professional certificates, and degree programs. It features an expansive content library spanning technology, business, data science, health, and personal growth to serve individual learners, businesses, and academic institutions worldwide.

In digital learning, Coursera’s blended model offers a combination of self-paced and instructor-led education content, offering flexibility and scalability. Its Coursera for Business and Coursera for Government segments enable organizations and governments to upskill workforces in critical areas like AI, cybersecurity, and digital transformation. Coursera’s emphasis on industry-validated credentials, micro-credentials, and complete degrees improves employability and career progression for learners. With the help of AI-powered personalization, mobile access, and localized content, Coursera has a robust international presence in 100+ countries.

LinkedIn Learning

LinkedIn Learning, a subsidiary of LinkedIn Corporation (owned by Microsoft), is a major player in the U.S. digital education market, offering a vast library of expert-led online courses across business, technology, and creative fields. Targeting professionals and organizations, it combines personalized learning paths with data-driven insights from LinkedIn’s platform to enhance career development and workforce upskilling. With its integration into LinkedIn profiles and enterprise tools, it plays a strategic role in corporate training and lifelong learning, catering to both individuals and businesses seeking to stay competitive in a rapidly evolving job market.

Pluralsight

Pluralsight is a U.S.-based e-learning company headquartered in Draper, Utah, specializing in technology-focused professional development. Targeting software developers, IT admins, and creative professionals, it delivers a subscription-based platform featuring thousands of expert-led video courses, skill and role assessments (Skill?IQ and Role?IQ), certification prep, guided learning paths, hands-on labs, and real-time mentoring. With over 7,000 courses created by more than 1,400 subject-matter experts and enterprise adoption by roughly 70% of Fortune?500 firms as of 2019, Pluralsight is a major player in the U.S. digital education market—especially in B2B upskilling and workforce transformation.

edX

edX, founded in 2012 by Harvard and MIT and now a subsidiary of 2U, Inc., is a U.S.-based leader in the digital education market, offering over 3,000 online courses, MicroBachelors, MicroMasters, professional certificates, and full degree programs from more than 155 university and organizational partners. With around 83?million registered learners in 2023 and roughly half based in the U.S., the platform serves both individuals and enterprises through its edX for Business offering, which integrates into the LinkedIn Learning Hub for curated, data-driven skill development. Leveraging its open-source Open edX infrastructure and high-profile partnerships like AWS’s Professional Certificate in Cloud Solutions Architecture launched in February 2023, edX stands out for delivering university-level, stackable credentials designed to meet evolving workforce and academic needs.

Udacity

Udacity is a U.S.-based for-profit online education provider, founded in 2011 by Sebastian Thrun, David Stavens, and Mike Sokolsky, and now owned by Accenture (acquired in March 2024). Specializing in career-focused tech training, it offers Nanodegree programs and individual courses in AI, data science, programming, cloud computing, autonomous systems, and more—developed in partnership with industry leaders like Google, IBM, Amazon, Microsoft, and NVIDIA. With 16?M+ registered users, 205?K Nanodegree certificates awarded, robust enterprise adoption by major companies and governments, and recognition as a “Leader” by IDC in U.S. IT training, Udacity plays a prominent role in the U.S. digital education market—specifically in B2B upskilling and digital workforce transformation.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/digital-education-market-7751828.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Digital Education Market Outlook 2030: Growth Strategy, Outlook, Opportunities, Trends, and Top Key Player

Solar Panel Recycling Market 2025: Business Strategies for Excellent Growth, Highest Revenue, Booming Growth Opportunities – 2030

The Solar Panel Recycling Market is gaining momentum due to the rising volume of decommissioned panels and growing environmental regulations. As the global solar capacity expands, recycling offers sustainable solutions for valuable material recovery. Key players such as First Solar, Recycle Solar Technologies, Veolia, and Cleanlites are leading innovations in end-of-life panel management, contributing to a circular economy in the solar industry.

The solar panel recycling market size is projected to grow from USD 0.39 billion in 2024 to USD 1.12 billion by 2030, registering a CAGR of 19.5% during the forecast period. The Research report presents a complete judgment of the market which consists of future trends, solar panel recycling market growth factors, consumption, production volume, CAGR value, attentive opinions, profit margin, price, and industry-validated market data.

A number of factors are creating demand for the solar panel recycling market. Increased adoption of solar energy around the world is leading to an increasing number of end-of-life panels that need to be disposed of. Environmental regulations and government policies related to the environment, encourage the responsible disposal of solar panels by proper recycling, as well as promoting circular economy waste practices. Authorization of the environmental dangers related to the improper disposal of solar panels has led to the urgent need for the more environmentally friendly recycling of these panels. In addition, there is an economic incentive based on the recovery of materials such as silicon, silver, and aluminum from panels that have been disposed of as well.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2927896

Polycrystalline is anticipated to be the largest segment of the solar panel recycling market, based on type, during the forecast period

Polycrystalline panels accounted for the largest market share of the solar panel recycling market mainly because they are used extensively in initial solar installations and are relatively affordable to manufacture. The panels have been the most preferred type for large-scale solar installations for the last two decades, particularly in the emerging and price-conscious markets, because of their relatively lower production cost compared to monocrystalline types. Consequently, a large proportion of old and retired solar panels that make it to the recycling pipeline today are polycrystalline. Polycrystalline panels have recoverable materials like glass, aluminum, and silicon that are easy to recover, making mechanical recycling techniques more viable and cost-effective. Their less complex cell structure also makes dismantling easier, with shorter processing time and cost.

Early loss is anticipated to be the larger segment of the solar panel recycling market, based on shelf life, during the forecast period

Early loss accounted for the larger market share of the solar panel recycling market due to the failure and premature disposal of early-installed panels as a result of unexpected failure. Most of these early-generation panels experienced defects during manufacture, were poor-quality materials, or where installation methods were inferior, resulting in compromised performance and reliability. The rapid development of solar tech has also led some system owners to upgrade to new, more efficient panels earlier than their life expectancy, adding volumes of discarded panels. In contrast to panels reaching their typical end-of-life, early-loss panels are entering the recycling stream in greater-than-expected volumes, spurring an immediate demand for recycling solutions.

Hybrid is anticipated to be the larger segment of the solar panel recycling market, based on process, during the forecast period

Hybrid recycling accounted for the higher share of the solar panel recycling market due to its ability to achieve maximum material recovery and meet the continuous demand for materials in the marketplace. Unlike pure mechanical recycling, hybrid recycling offers a way to extract a broader range using mechanical, thermal, and chemical processes and yields high-purity silicon, silver, and rare metals. Hybrid methods will be especially effective for modern, high-efficiency solar panels with more complex materials, such as monocrystalline solar panels, which have ultimately combined and integrated various technologies. As environmental regulations become stricter to promote a circular economy, hybrid recycling provides value in sustainability and economic prosperity with less waste sent to landfills, increased recovery of critical raw material, and advanced recovery choices. Additionally, with increasing investments into advances in recycling processes, hybrid recycling will be an efficient, scalable, and commercially viable commitment for businesses.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=2927896

Metal is anticipated to be the largest segment of the solar panel recycling market, based on material, during the forecast period

Metals accounted for the largest share of the solar panel recycling market because they represent a larger share of valuable, reclaimable materials in photovoltaic panels. Aluminum, copper, and silver are some of the key metals that are used as materials in the frames of panels, wiring, and contacts and, therefore find high demand in recycling processes. Aluminum frames, especially, are present in high volumes and are easy to differentiate, which allows inexpensive recycling with high rates of recovery. Silver and copper, although they occur in lesser amounts, contribute significant economic value based on their relatively high market values and usage in different industries. Metals retain their properties when they are recycled and hence reused in producing new materials, contributing to circular economy objectives. The fact that metals are relatively easy to extract compared to other intricate materials such as silicon or plastics significantly increases their dominance in the recycling industry.

Europe is expected to be the largest region of the solar panel recycling market during the forecast period

Europe holds the largest market share in solar panel recycling due to its robust regulatory framework, advanced recycling infrastructure, and an overall commitment to sustainability. European countries have established comprehensive policy frameworks and targets to manage photovoltaic waste properly, stimulating investments in specialized recycling units. The relatively early adoption of solar energy in Europe means that a significant amount of panels have reached or are approaching the end-of-life, further pushing the demand for recycling facilities. The region’s emphasis on circular economy principles presents further opportunities for recycling as it encourages the recovery and reuse of economically valuable materials from solar panels, such as silicon, glass, or metals, as needed. With significant levels of both, public awareness and government support promoting green initiatives, conditions appear to be favorable for a rapidly growing emerging market for solar panel recycling.

Solar Panel Recycling Companies

To enable an in-depth understanding of the competitive landscape, the report includes the profiles of some of the top players in the solar panel recycling market. First Solar (US), Reiling GmbH & Co. KG (Germany), The Retrofit Companies, Inc. (US), Rinovasol Global Services B. V. (Netherlands), ROSI (France), We Recycle Solar (US), SILCONTEL LTD (Israel), Etavolt Pte. Ltd. (Singapore), PV Industries (Australia), and SOLARCYCLE, Inc. (US).

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=2927896

First Solar is a prominent American solar technology company renowned for providing photovoltaic (PV) solar energy solutions globally. Renowned for its innovation, its PV solar modules are developed in cutting-edge research & development (R&D) labs in California and Ohio. These modules boast the advanced thin-film semiconductor technology, offering high performance and a lower-carbon alternative to conventional crystalline silicon PV solar modules. From inception to disposal, First Solar is dedicated to minimizing the environmental impact and enhancing its products’ social and economic benefits across their entire life cycle. As the largest thin-film PV solar module manufacturer worldwide and the largest in the Western Hemisphere, the company operates across two primary segments, namely, Modules and Others. First Solar operates high-value recycling facilities in the US, Germany, India, Malaysia, and Vietnam, capable of recycling approximately 2.6 million solar modules per year. The company maintains a global presence across various regions, including North America, South America, Asia Pacific, Africa, and Europe.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/solar-panel-recycling-market-2927896.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Solar Panel Recycling Market 2025: Business Strategies for Excellent Growth, Highest Revenue, Booming Growth Opportunities – 2030

Virtual Data Room Market Latest Trends, Outlook, Global Size, Share, Applications, Advance Technology And Forecast – 2029

“SS&C Intralinks (US), Box (US), Datasite (US), Thomson Reuters (Canada), Donnelley Financial Solutions (US), Microsoft (US), Google (US), Ansarada (Australia), PandaDoc (US), Egnyte (US), iDeals (UK), SmartRoom (US), Vitrium Security (US), ShareVault (US), ForData (Poland), EthosData (UK).”
Virtual Data Room Market by Data Storage & Management (Database, Content), Security (Encryption, DRM, DLP), Document Type (Contracts & Agreements, IP), Application (M&A Due Diligence, Document Management, Audit, Compliance) – Global Forecast to 2029.

The global virtual data room market is expected to grow at a compound annual growth rate (CAGR) of 18.1% over the course of the forecast period, from an estimated USD 2.5 billion in 2024 to USD 5.6 billion by 2029. Key drivers of market expansion include the need to improve stakeholder collaboration and expedite the due diligence process, the growing need for hierarchical document organization for ease of navigation, and the ability to provide unified and centralized access points for evaluating and effectively sharing digital documents.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74439915

“Increasing demand for hierarchical document organization for ease of navigation.”

The market is expected to grow due to the capability of offering centralized access points for shared digital documents, which reduces time of managing multiple documents from single platform. The increasing demand for document organization simplifies access to specific documents, as virtual data room offers a safe and integrated platform, which improves user experience during audits and transactions and assists real-time collaboration.

“By Software type, the AI-assisted Redaction segment registers for the fastest growing market during the forecast period.”

As businesses increasingly manage large volumes of confidential information, manual redaction becomes inefficient and error prone. AI-driven tools can swiftly identify and redact sensitive data across various document types, reducing the risk of human error and ensuring compliance with data protection regulations. Additionally, the growing adoption of AI technologies across industries and the need for secure, efficient data management solutions drive demand for AI-assisted redaction software, making it a key growth area in the virtual data room market.

“By region, Asia Pacific to register the highest CAGR market during the forecast period.”

The increase of mergers and acquisition activities, cross and the rising need for secure data management in emerging economies like China, India, and Southeast Asia. The region’s expanding tech infrastructure, coupled with growing awareness of data privacy regulations, drives demand for virtual data room. Additionally, a surge in cross-border transactions and investments in sectors such as technology, finance, and healthcare further fuel the market. Government initiatives promoting digital transformation and foreign investments also contribute to the region’s accelerated growth in the virtual data room sector.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=74439915

Unique Features in the Virtual Data Room Market

Modern VDR platforms integrate artificial intelligence (AI) to enhance document analysis and deal-making. Features such as automated document indexing, keyword detection, and sentiment analysis help streamline due diligence and provide actionable insights into user behavior, improving decision-making.

VDRs enable highly granular permission settings, allowing administrators to define view, print, download, and edit rights for individual users or groups. This capability is essential for managing sensitive information, particularly in mergers and acquisitions (M&A), audits, and legal case management.

Virtual Data Rooms now offer integration with enterprise applications like Microsoft 365, Google Workspace, Salesforce, and DocuSign. This interoperability improves workflow efficiency by enabling document collaboration, digital signatures, and real-time updates within familiar environments.

Advanced VDRs provide built-in communication features such as Q&A sections, threaded discussions, annotations, and live chat. These capabilities support faster deal-making and collaboration between internal and external stakeholders, eliminating the need for separate communication tools.

Major Highlights of the Virtual Data Room Market

The Virtual Data Room market is witnessing robust growth driven by the surge in mergers and acquisitions, particularly across sectors like banking, pharmaceuticals, and technology. Organizations increasingly rely on VDRs to streamline due diligence, ensuring secure and efficient access to sensitive documents during deal-making processes.

While large enterprises have traditionally led the VDR adoption curve, there is a notable increase in usage among small and medium-sized enterprises (SMEs), especially in emerging markets. The flexibility, affordability, and scalability of cloud-based VDRs make them attractive for growing businesses managing fundraising, joint ventures, and regulatory compliance.

AI integration is transforming the VDR landscape by automating repetitive tasks, enhancing data accuracy, and providing predictive insights. Features like auto-indexing, smart redaction, and AI-driven risk detection are becoming standard, enabling faster and more intelligent document review processes.

With growing global emphasis on data privacy and cybersecurity regulations such as GDPR, CCPA, and HIPAA, organizations are prioritizing secure data sharing solutions. VDRs are emerging as a trusted method for meeting compliance requirements while maintaining auditability and confidentiality.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=74439915

Top Companies in the Virtual Data Room Market

Top virtual data room Market companies as SS&C Intralinks (US), Box (US), Datasite (US), Thomson Reuters (Canada), Donnelley Financial Solutions (US), Microsoft (US), Google (US), Ansarada (Australia), PandaDoc (US), Egnyte (US), iDeals (UK), SmartRoom (US), Vitrium Security (US), ShareVault (US), ForData (Poland), EthosData (UK), CapLinked (US), Imprima (UK), Midaxo (US), FuseBase (US), Onit (US), FirmsData (India), Confiex Data Room (India), Drooms (Switzerland), Bit.ai (US), DCirrus (India), Virtual Vaults (Netherlands), Firmex (US), Deallink (Brazil), PactCentral (US), DocullyVDR (UAE).

SS&C Intralinks

SS&C Intralinks stands out in the virtual data room market due to its robust suite of features and advancements that cater to diverse transactional needs. One of its key strengths is its secure and scalable platform, which ensures the confidentiality and integrity of sensitive information. Its flagship product, VDRPro, which offers advanced security features and a user-friendly interface for managing sensitive documents during complex transactions. VDRPro is designed to streamline due diligence, mergers, and acquisitions with its comprehensive suite of tools, including customizable workflows, real-time document tracking, and secure data sharing. SS&C Intralinks also excels in integrating AI and machine learning into its virtual data room solutions, enhancing document analysis, and facilitating more efficient data management. Their commitment to continuous advancement ensures that clients benefit from innovative technology and improved operational efficiency. The combination of security, functionality, and innovation positions SS&C Intralinks as a leading provider in the virtual data room market, catering to the evolving needs of financial, legal, and corporate sectors.

Datasite

Datasite is one of the leaders in the virtual data room market, renowned for its comprehensive and user-friendly platform tailored for complex financial transactions. Its flagship product, Datasite Diligence, excels in streamlining due diligence processes with robust features like AI-powered document indexing and advanced search capabilities. Enhancements such as integrated analytics, automated redaction, and seamless collaboration tools further elevate its offering, ensuring efficiency and security. Datasite’s commitment to innovation is evident in its continuous upgrades, including enhanced user interfaces and mobile accessibility. These strengths make Datasite a preferred choice for M&A professionals, legal advisors, and financial institutions, offering a reliable and efficient solution for managing confidential data in high-stakes transactions.

Box

Box excels in the virtual data room market with its robust security features, user-friendly interface, and seamless integration capabilities. It offers advanced encryption, granular permissions, and comprehensive audit trails, ensuring data integrity and compliance. Enhancements such as automated workflows, AI-driven data classification, and machine learning insights further elevate its functionality. Box’s virtual data room is designed for scalability and flexibility, making it suitable for businesses of all sizes. Its integration with popular productivity tools and enterprise applications enhances collaboration and efficiency, solidifying Box’s position as a leading provider in the virtual data room market.

Thomson Reuters

Thomson Reuters is a Canadian multinational corporation headquartered in Toronto, specializing in providing professionals with trusted content and workflow automation solutions. The company serves various sectors, including legal, tax and accounting, risk and fraud, trade and supply, and news and media. Leveraging over 150 years of expertise, Thomson Reuters integrates artificial intelligence and technology to help professionals navigate complex landscapes and make informed decisions. Under the leadership of CEO Steve Hasker since 2020, the company has emphasized a cloud-first strategy and the incorporation of generative AI technologies across its products, particularly benefiting its legal and accounting divisions. In 2023, Thomson Reuters announced plans to implement a paid subscription model for its digital news content, starting with a $1 per week fee in Canada, reflecting a broader industry trend towards diversified revenue sources.

Donnelley Financial Solutions

Donnelley Financial Solutions (DFIN) is an American financial compliance company based in Chicago, Illinois. Established as an independent entity in 2016 after spinning off from RR Donnelley, DFIN provides software-as-a-service (SaaS) products, software-enabled services (SeS), print, and compliance services related to U.S. Securities and Exchange Commission regulations.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/virtual-data-room-market-74439915.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Virtual Data Room Market Latest Trends, Outlook, Global Size, Share, Applications, Advance Technology And Forecast – 2029

North American Air Circuit Breaker Market worth $1.08 billion by 2030

The North American Air Circuit Breaker Market is projected to reach USD 1.08 billion by 2030 from an estimated USD 0.82 billion in 2025 at a CAGR of 5.7% during the forecast period

The North American Air Circuit Breaker Market is projected to grow from estimated USD 0.82 billion in 2025 to USD 1.08 billion by 2030, at a CAGR of 5.7% during the forecast period. The North American Air Circuit Breaker (ACB) Market is likely to continue experiencing steady growth up to 2030, driven by growing investments in grid modernization, industrial automation, and renewable energy infrastructure in the United States and Canada. With aging legacy electrical systems and the growing need for uninterrupted power supply, utilities, commercial buildings, and industrial plants are turning toward ACBs due to their reliability, superior breaking capacity, and simplicity of integration with smart monitoring systems. Federal investment programs such as the IIJA (Infrastructure Investment and Jobs Act) and the Inflation Reduction Act are directing significant investment toward developing substations, transmission infrastructure, and power distribution systems. ACBs have an essential function in protection and load control. Besides that, the growth in renewable energy installations, electric vehicle charging points, and data centers has increased demand for high-endurance, flexible switchgear that can handle load fluctuations and grid complexity, further supporting the demand for air circuit breakers. Technological improvements in arc flash protection, remote diagnostics, and modular designs improve ACB applicability in today’s power infrastructure. As the North American continent moves toward a digital, resilient, and sustainable grid power infrastructure, there are enormous opportunities for ACB manufacturers to address transforming utility, commercial, and industrial needs with next-generation technologies.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51384614

Air blast circuit breakers are expected to hold larger market share throughout forecast period

The air blast circuit breaker segment is expected to capture a significant share of the North American Air Circuit Breaker Market during the forecast period because of its better performance traits and applicability in medium-voltage and high-demand applications. Air blast circuit breakers utilize compressed high-pressure air to rapidly and effectively extinguish arcs, and as such, are suited for applications that demand the high-speed interruption of fault currents, such as power plants, industrial substations, and extensive business complexes. Their high-speed performance capability to manage frequent operations and guarantee greater electrical safety ranks them higher than simple air circuit breakers in mission-critical applications. In addition, air blast breakers generally represent lower maintenance requirements and longer life cycles, which add to their attractiveness for utility and industrial customers looking for long-term dependability and operational efficiency. As North America continues replacing aging infrastructure and incorporating renewable energy and distributed generation, demand for high-performance, arc-resistant switching technologies such as air blast circuit breakers is anticipated to grow steadily.

Low voltage segment to account for majority of market share throughout forecast period.

The low-voltage segment is anticipated to hold a larger market share of the North American Air Circuit Breaker Market during the forecast period, owing to its extensive usage in industrial, commercial, and infrastructure sectors. Low-voltage air circuit breakers, rated below 1 kV, play a vital role in the protection of electrical circuits in industrial plants, commercial facilities, data centers, hospitals, and institutional building environments where electrical security, equipment protection, and continuity of power are paramount. They are preferred due to their simplicity of installation, economic implications, and compatibility with intelligent monitoring systems and are, therefore, appropriate for contemporary energy management approaches. Also, contributing to the growth is the relentless growth of data centers, fast-paced commercial growth, and the upgrading of electrical infrastructure in cities throughout the US and Canada. As the focus on energy efficiency, automation, and smart grid compatibility intensifies, the low-voltage ACB segment is poised to continue leading the market.

US to lead North American air circuit breaker market

During the forecast period, the US is expected to dominate the North American Air Circuit Breaker Market due to massive infrastructure upgrades, increasing industrial automation, and robust policy support for clean energy integration and grid reliability. As the American government launches projects under the Infrastructure Investment and Jobs Act (IIJA) and the Inflation Reduction Act (IRA), considerable investments are going into modernizing substations, replacing old switchgear, and making power distribution networks more resilient. The nation’s strong industrial sector, increasing data center count, and increasing use of clean energy sources such as wind and solar have increased the need for smart air circuit breakers to manage power safely and efficiently. Moreover, the mandatory safety measures and energy efficiency standards imposed by organizations such as the US Department of Energy (DOE) are speeding up the integration of smart, low-maintenance ACBs for digital monitoring. Based on a well-developed electrical infrastructure and aggressive efforts in energy transition, the US will lead the region’s market in terms of volume and value.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=51384614

Key Players

Some prominent players in the North American Air Circuit Breaker Market are ABB Ltd. (Switzerland), Schneider Electric (France), Mitsubishi Electric Corporation (Japan), Eaton (Ireland), and Siemens AG (Germany). These players aggressively invest in product innovation, regional production expansion, and strategic acquisitions to meet the region’s increasing demand for sophisticated circuit protection systems. As North America’s electrical infrastructure undergoes digitalization, decarbonization, and decentralization efforts, these companies target intelligent air circuit breakers with IoT-based monitoring, arc flash protection, and remote diagnostic capabilities. The focus is on providing compact, cybersecure, and easy-to-maintain ACBs capable of facilitating renewable energy integration, critical infrastructure, and high-density urban developments. Partnerships with utilities, electric contractors, and grid operators form the core of their plans, particularly in aligning the design of products with changing safety codes such as UL, IEEE, and NEC standards. In addition, further investment in domestic manufacturing and R&D facilities in the US and Canada makes it possible to achieve quicker delivery cycles, customized product configurations, and compliance with federal infrastructure programs, cementing these companies’ leadership roles in industrial, commercial, and utility markets.

ABB (Switzerland)

ABB (Switzerland) is a global technology leader in electrification and automation that offers a complete line of low- and medium-voltage air circuit breakers across North America for industrial, utility, and infrastructure purposes. Its Emax and Tmax ACBs are widely used across mission-critical environments and enable intelligent protection, load management, and energy monitoring capabilities in all applications. ABB understands and embraces digital power management, as its ACBs integrate with digital solutions inherently, and its ACBs also feature communication protocols such as Modbus and Ethernet, which allow for rapid adoption of Industry 4.0. Aside from established channels, ABB invests heavily in emerging technologies such as predictive diagnostics, arc flash protection technologies, and compact modular designs that minimize space and keep workers safe working in data centers, commercial buildings, and industrial plants. ABB is increasingly embracing sustainability through its EcoSolutions product line, which includes air circuit breakers manufactured with recycled materials and a reduced CO2 footprint. In North America, ABB persists in developing its service and distribution network and working with EPCs, OEMs, and utilities on modernization and electrification initiatives under federal energy programs.

Schneider Electric (France)

Schneider Electric (France) is one of the key manufacturers in the North American ACB market. It supports market evolution with advanced and digitally connected solutions through its MasterPact and ComPact ACB brands. Schneider Electric embedded advanced digital trip units into its air circuit breakers (ACBs) to provide smart capabilities, such as real-time data acquisition, fault diagnostics, and remote operation, to better protect its customers’ industrial and commercial facilities. Schneider Electric met the stressed energy management, operational safety, and regulatory compliance demands of the electricity grid and corporate responsibility for safety, decarbonization, and net-zero transitions of power-critical spaces in healthcare, manufacturing, and data center markets. Its EcoStruxure platform connects ACBs to cloud-based analytics that assess energy demands to assist with load optimization, condition monitoring, and predictive maintenance solutions. Schneider Electric in North America is increasing its manufacturing footprint and investing in partnerships with local utilities, contractors, and systems integrators to provide market access and knowledge on innovative infrastructure development. While investing in social impact initiatives, Schneider Electric is committed to decarbonization and resiliency by developing energy-efficient and low-GWP ACB systems that align with education on developing green building codes and net-zero environmental targets.

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: newsletter@marketsandmarkets.com

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/north-american-air-circuit-breaker-market-51384614.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: North American Air Circuit Breaker Market worth $1.08 billion by 2030

Hospital Filtration Market Analysis by Size, Share, Growth, Sourcing Strategy, Scope, Demand and Forecast to 2030

The Hospital Filtration Market is witnessing robust growth driven by increasing demand for infection control and improved air quality in healthcare facilities. Advancements in HEPA and ULPA filter technologies are enhancing filtration efficiency. Key players such as 3M, Camfil, Parker Hannifin, MANN+HUMMEL, and AAF International are actively innovating to meet stringent regulatory standards and support cleaner hospital environments worldwide.

The global hospital filtration market is projected to grow from USD 2.10 billion in 2024 to USD 3.19 billion by 2030, at a CAGR of 7.2%. The Research report presents a complete judgment of the market which consists of future trends, hospital filtration market growth factors, consumption, production volume, CAGR value, attentive opinions, profit margin, price, and industry-validated market data.

The hospital filtration market is experiencing significant growth due to increasing demand from various major economies for different applications such as hospital facilities, laboratories, and other applications as well. Air & water Filtration products reduce the contamination from air & water. They help to maintain clean and sterile environment, which is very important for patient and doctors’ safety. This market is driven by stringent regulations, huge investment in healthcare infrastructure, and focus on patient safety. North America to be the largest market for hospital filtration followed by Europe. Asia Pacific is expected to be the fastest growing market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=251534296

Inline filters, is expected to be second largest segment by type during the forecast period

Inline filters are crucial elements of a filtration system in hospitals as they offer decontamination processes for the targeted pollutants from the air or water pipelines. These filters remove particles, bacteria, and other fine impurities to ensure that clean air and water is available for use on sensitive applications such as surgical equipment, dialysis machines, and sterilization units. Their small size makes their incorporation into existing systems easy, so they are perfect for maintaining hygiene in areas of high risk such as operating rooms, ICUs, and isolation wards. Moreover, inline filters are also considered to be economical as their low maintenance ensures continuous filtration, with no interruptions to the everyday workings of the hospital.

Sterile environment, is expected to be fastest growing segment by form during the forecast period.

The term sterile environment denotes controlled spaces that are devoid of any microorganisms such as viruses, bacteria, fungi, and spores achieving the highest degree of cleanliness and safety. Correlatively, health structures should strictly uphold the standards of the sterile environment in areas like operating rooms, ICUs, and laboratories in order to prevent the possibility of infection and protect the patients’ well being. Filtration devices are critical in creating these conditions. HEPA (High-Efficiency Particulate Air) and ULPA (Ultra-Low Penetration Air) are HVAC system filters that capture airborne and other pathogenic particulates. Point-of-use filters are used for localized water treatment to remove bacteria and other contaminants. Together, these filtration products ensure sterile air and water, reducing healthcare-associated infections (HAIs) and enhancing patient safety.

Laboratories, is expected to be second largest segment by application during the forecast period.

Filtration systems in laboratories are one of the critical application fields of hospital filtration systems, given that a contamination-free environment is required for testing, conducting research, and diagnostics. Air and water in the laboratories also require filtration to get rid of airborne particulates, any existing pathogens, chemical fumes, and waterborne contaminants. To ensure cleanroom standards, high-efficiency particulate air (HEPA) filters, and ultra-low penetration air (ULPA) filters are utilized. Furthermore, RO systems and deionized water systems are used to supply sensitive equipment and experiments with ultra-pure water. These measures guarantee the safety of employees, results’ accuracy, and adherence to particular regulations in the health care and research centers.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=251534296

North America is expected to be the largest region in the global hospital filtration market in terms of value during the forecast period.

Countries considered in the North America region are US, Canada and Mexico. Hospital filtration are witnessing increasing demand in the region due to the huge investment in healthcare infrastructure, stringent regulations, focus on patient safety. The economic development and growth in various countries in this region lead to an expansion in the North American hospital filtration market.The US is the largest market for hospital filtration in North America followed by Canada owing to the large population, focus on infection control, high adoption of technology, increasing healthcare expenditure, growing aging population and pandamic preparedness.

Hospital Filtration Companies

To enable an in-depth understanding of the competitive landscape, the report includes the profiles of some of the top players in the hospital filtration market. These includes Danaher (US), Veolia (France), Pentair (US), Merck KgaA (Germany), Daikin Industries (Japan), Camfil (Sweden), Freudenberg Technologies (Germany), Solventum (US), Sartorius AG (Germany), and Parker Hannifin Corp. (US)

Danaher is a global leader in life sciences and diagnostics innovation, dedicated to addressing some of the world’s most critical health challenges. Danaher consists of over 15 operating companies that hold leadership positions in the biotechnology, life sciences, and diagnostics sectors, organized into three main segments: Biotechnology, Life Sciences, and Diagnostics. The company offers hospital filtration and other products through Cytiva company. Cytiva’s product portfolio includes aseptic filling machines, bioreactors, fermenters, cell therapy solutions, chromatography products, fluid handling systems, connectors, mixers, lab filtration products, hospital filtration products, nanoparticle formulation system, medical products, protein analysis equipment, and others. In hospital filtration, company offers breathing system filter, gas line filter, IV filters, water filters, syringe filter, intensive care breathing filter, surgical gas filter and other products. The company’s product line is used in various applications such as bioprocessing, lab filtration, cell & gene therapy, protein research, genomics and others. Danaher has global presence, its research and development, manufacturing, sales, distribution, service and administrative facilities are in more than 50 countries.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=251534296

Veolia is a leader in environmental services. It provides complete range of solutions for managing Water, Waste and Energy. The company operates through three business segments: water, energy, and waste management. The company offers water filtration products through its subsidiary, Veolia Water Technologies. The company offers various hospital filtration products under the brand OSIRIS, Thermapure, Medica, PureLab, Integra and others. Veolia offers its products and solutions in 52 countries across North America, Middle East & Africa, Latin America, Asia Pacific, Europe, and Australia.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/hospital-filtration-market-251534296.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hospital Filtration Market Analysis by Size, Share, Growth, Sourcing Strategy, Scope, Demand and Forecast to 2030

$150 Trillion Mineral Wealth Could Transform U.S. Economy, Expert Says

Jim Rickards: “America isn’t broke — we’re sitting on a fortune.”

WASHINGTON, D.C. – July 1, 2025 – As the U.S. grapples with a national debt exceeding $34 trillion, a massive $150 trillion in untapped mineral reserves beneath federal lands could offer a game-changing solution, according to Jim Rickards, a former advisor to the CIA, Pentagon, and U.S. Treasury.

“This wealth could pay off the national debt multiple times over,” Rickards asserts. “It’s time to debunk the myth that America is broken.”

A Hidden Economic Powerhouse

Buried beneath public lands, these reserves — rich in copper, lithium, rare earth elements, and other critical minerals — have been locked away for decades by regulatory restrictions. Now, emerging opportunities are bringing these resources within reach.

“We’re on the verge of accessing this enormous asset,” Rickards says. “This could redefine America’s economic future.”

With global demand for minerals surging due to technology and clean energy needs, tapping these reserves could position the U.S. as a leader in the global economy.

Reviving a Historic Opportunity

In the 1800s, America’s public lands were a springboard for wealth creation, turning dreams of “rags to riches” into reality. Over time, regulations restricted access, leaving these resources largely untapped. Today, the potential to unlock these reserves could spark a new era of prosperity.

“This isn’t a government handout,” Rickards emphasizes. “It’s an opportunity for businesses, investors, and everyday Americans to benefit from a resource that’s part of our nation’s foundation.”

A Path to Economic Strength

Rickards argues that leveraging these minerals could address economic challenges without raising taxes or increasing foreign borrowing. “Trillions of dollars in wealth lie beneath our soil,” he says. “Accessing it could drive unprecedented growth.”

Experts suggest that tapping these reserves could create millions of jobs, bolster domestic manufacturing, and secure supply chains for critical technologies like electric vehicles and renewable energy systems.

Why This Matters Now

As global competition for resources intensifies, unlocking America’s mineral wealth could strengthen national security by reducing reliance on foreign supplies. It also offers a chance to stabilize the economy and fuel growth for generations.

“This is about harnessing our nation’s potential,” Rickards says. “The wealth is here — we just need to act.”

About Jim Rickards

Jim Rickards, a leading economic strategist, served as an advisor to the CIA, Pentagon, and U.S. Treasury. With an esteemed career shaping geopolitical policies, including the Petrodollar Accord and crisis-era responses, he now edits Strategic Intelligence, providing insights on economic trends, national security, and global opportunities.

Media Contact:

Derek Warren

Public Relations Manager

Paradigm Press Group

Email: dwarren@paradigmpressgroup.com

To view original press release on PR Gun, please visit https://prgun.com/press-release/245886/150-trillion-mineral-wealth-could-transform-us-economy-expert-says

Media Contact
Company Name: Paradigm Press Group
Contact Person: Derek Warren – Public Relations Manager
Email: Send Email
City: Washington
State: D.C.
Country: United States
Website: https://pro.paradigmnewsletters.org/